214 related articles for article (PubMed ID: 12034106)
21. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination.
Dilraj A; Sukhoo R; Cutts FT; Bennett JV
Vaccine; 2007 May; 25(21):4170-4. PubMed ID: 17408818
[TBL] [Abstract][Full Text] [Related]
22. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
Kremer JR; Schneider F; Muller CP
Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
[TBL] [Abstract][Full Text] [Related]
23. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis.
Low N; Kraemer S; Schneider M; Restrepo AM
Vaccine; 2008 Jan; 26(3):383-98. PubMed ID: 18082295
[TBL] [Abstract][Full Text] [Related]
25. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z
Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780
[TBL] [Abstract][Full Text] [Related]
26. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine].
Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L
Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334
[TBL] [Abstract][Full Text] [Related]
27. The national measles and rubella campaign--one year on.
Commun Dis Rep CDR Wkly; 1995 Nov; 5(45):237. PubMed ID: 8541943
[No Abstract] [Full Text] [Related]
28. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M; Kanra G; Erdem G; Kanra B
Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
[TBL] [Abstract][Full Text] [Related]
30. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
Just M; Berger R; Glück R; Wegmann A
Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
[TBL] [Abstract][Full Text] [Related]
31. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts.
Davidkin I; Valle M
Vaccine; 1998 Dec; 16(20):2052-7. PubMed ID: 9796064
[TBL] [Abstract][Full Text] [Related]
32. [Phases 3 and 4 immunization immunogenicity with combined measles-rubella vaccine].
Ozaki T; Nishimura N; Gotoh K; Ohe K; Funahashi K; Maeda K; Okuno Y
Kansenshogaku Zasshi; 2011 May; 85(3):250-5. PubMed ID: 21706844
[TBL] [Abstract][Full Text] [Related]
33. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
[TBL] [Abstract][Full Text] [Related]
34. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
Klinge J; Lugauer S; Korn K; Heininger U; Stehr K
Vaccine; 2000 Jul; 18(27):3134-40. PubMed ID: 10856793
[TBL] [Abstract][Full Text] [Related]
35. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
[TBL] [Abstract][Full Text] [Related]
36. Serological evaluation of a measles, mumps, and rubella vaccine.
Robertson CM; Bennett VJ; Jefferson N; Mayon-White RT
Arch Dis Child; 1988 Jun; 63(6):612-6. PubMed ID: 3291787
[TBL] [Abstract][Full Text] [Related]
37. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds.
Krober MS; Stracener CE; Bass JW
JAMA; 1991 Apr; 265(16):2095-6. PubMed ID: 2013930
[TBL] [Abstract][Full Text] [Related]
38. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
40. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
Trier H; Rønne T
Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
